Spectranetics Named Company of the Year at Colorado Springs Regional Business Alliance Annual Gala

The Spectranetics Corporation was named the 2014 Company of the Year at the Colorado Springs Regional Business Alliance Annual Gala at The Broadmoor on Sat., Nov. 1, 2014.  The award is given annually to a local business that demonstrates a significant impact on its industry and a considerable increase in revenues or profits.

“Spectranetics has been an active member of the Colorado Springs business community for 30 years.  We are proud of our longtime roots and the contributions we make to the local economy through jobs, travel and hospitality spending, charitable donations and innovation. Doing business here is a pleasure. We are honored to be recognized,” states Guy Childs, chief financial officer, Spectranetics.
 
Spectranetics was one of the first companies to explore the use of an ultraviolet laser to clear occluded arteries. Today, the company’s business is diversified and thriving.  Spectranetics’ revenue has grown from $117.9 million in 2010 to a projected over $200 million in 2015.
 
Over the last three years, Spectranetics’ stock price has increased nearly five-fold and its market capitalization has surged from $170 million to $1.3 billion. The company just posted its thirteenth consecutive quarter of double digit growth in the peripheral atherectomy business.
 
In July, after a seven-year investment and groundbreaking clinical trial, Spectranetics’ received FDA indication for the use of laser atherectomy in the treatment of in-stent restenosis, presenting a $350 million market opportunity in the United States, $750 million worldwide.
 

About Spectranetics

Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
 
In June 2014, Spectranetics acquired AngioScore Inc., a leading developer, manufacturer and marketer of cardiovascular, specialty balloons. On November 2, 2014, SPNC announced a definitive agreement under which it will acquire Covidien’s Stellarex™ drug coated angioplasty balloon (DCB) platform for $30 million. The transaction is subject to approval by the Federal Trade Commission and other regulatory agencies, as well as closure of the pending acquisition of Covidien by Medtronic, which is expected to occur in early 2015.  
 
The Company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee as well as the AngioSculpt scoring balloon used in both peripheral and coronary procedures. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
 
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
 
For more information, visit www.spectranetics.com.